Champignon Secures Stable Psilocybin Supply Under DEA Schedule I License for TBI/PTSD Studies at the University of Miami

香菇在DEA附表下保证稳定的psilocybin供应--迈阿密大学TBI/PTSD研究许可证

2020/04/22 15:04  Champignon Brands Inc.

VANCOUVER, British Columbia, April 22, 2020 (GLOBE NEWSWIRE) -- Champignon Brands Inc. (“ Champignon ” or the “ Company ”) (CSE: SHRM) (FWB: 496) (OTC: SHRMF) , a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to advance its clinical pipeline via a long-term supply of psilocybin for its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine. The Company is pleased to announce that its research partner and lead investigator, Dr. Michael Hoffer, has secured a sustainable supply of psilocybin under a DEA schedule I license, which will be used for ongoing psilocybin-based therapeutics studies.

The psilocybin is to be provided by the same organization that has supplied both Johns Hopkins University and Yale University throughout their respective psilocybin research studies and trials. Under a collaborative research agreement with the University of Miami's Miller School of Medicine, Champignon’s 100%-owned subsidiary, Tassili Life Sciences Corp. (“Tassili”), is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. University of Miami’s Miller School of Medicine’s medical campus includes more than 500,000 square feet of research space, as well as a state-of-the-art, 1.8-million-square-foot, lab-ready research park. Final results of said studies and eventual trials are expected in 2021.

“We hope to continue to make significant progress on our preclinical trial studying the effects of an oral combination of psilocybin and CBD on mTBI associated with PTSD,” Dr. Hoffer commented. “Since mTBI associated with PTSD is a combination disorder that affects more than 10 million individuals per year and has no proven medical treatment, our novel combination of medicines could be a breakthrough in treating these indications.”

About Champignon Brands Inc.

Champignon Brands Inc. (CSE: SHRM) is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes for patients suffering with conditions like depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami's Miller School of Medicine, the Company is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at:https://champignonbrands.com/.

ON BEHALF OF THE BOARD OF DIRECTORS

W. Gareth Birdsall

CEO & Director

T: +1 (613) 967-9655

E:info@champignonbrands.com

FOR INVESTOR INQUIRIES:

Tyler Troup

Circadian Group

E: SHRM@champignonbrands.com

FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:

Remy Scalabrini

Maricom Inc.

E:rs@maricom.ca

T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for Champignon Brands described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available atwww.sedar.com.

不列颠哥伦比亚省温哥华,2020年4月22日(环球新闻社)--香菇品牌公司。(“香菇”或“公司”)(CSE:SHRM)(fWB:496)(场外交易代码:SHRMF),一家人类优化科学公司,专注于应用新颖和自然的治疗方案来解决广泛的疾病和缺陷,重点是迷幻药,继续通过长期供应psilocybin来推进其在迈阿密大学米勒医学院进行的以TBI/PTSD为重点的临床前研究。该公司高兴地宣布,其研究伙伴兼首席研究员迈克尔霍夫博士已根据DEA时间表I许可证获得了可持续的psilocybin供应,该许可证将用于正在进行的基于psilocybin的治疗学研究。

Psilocybin将由约翰霍普金斯大学(JohnsHopkins University)和耶鲁大学(YaleUniversity)在各自的psilocybin研究和试验过程中提供的同一组织提供。根据与迈阿密大学米勒医学院的合作研究协议,香菇100%的子公司塔西里生命科学公司。(“Tassili”),正在进行临床前研究和最终的人类临床试验,目的是证明psilocybin和canabidiol联合治疗mTBI合并PTSD或独立PTSD的安全性和有效性。迈阿密大学米勒医学院的医学院拥有超过50万平方英尺的研究空间,以及一个最先进的、180万平方英尺的实验室研究园区。上述研究和最终试验的最终结果预计将在2021年完成。

霍夫博士评论说:“我们希望在临床前试验中继续取得重大进展,研究口服联合应用psilocybin和CBD对PTSD相关的mTBI的影响。”“由于与PTSD相关的mTBI是一种综合障碍,每年影响超过1000万人,而且没有经过证实的药物治疗,我们的新型药物组合可能是治疗这些适应症方面的一个突破。”

香菇品牌公司简介

香菇品牌公司(CSE:SHRM)是一家研究驱动的公司,专门为营养、健康和替代医药行业开发一套药用蘑菇保健品以及新型氯胺酮、麻醉剂和适应原交付平台。香菇通过其垂直整合的替代药物系列,致力于开发和商业化快速发作疗法,以改善抑郁症、创伤后应激障碍(PTSD)以及物质和酒精使用障碍患者的健康状况。根据与迈阿密大学米勒医学院的一项合作研究协议,该公司正在进行临床前研究和最终的人类临床试验,目的是证明psilocybin和大麻二醇联合治疗mTBI和PTSD或单独PTSD的安全性和有效性。香菇继续受到可持续性的启发,因为它的药用蘑菇注入SKU是有机的,非转基因和素食认证。欲了解更多信息,请访问公司网站:https://champignonbrands.com/.

代表董事会

W.Gareth Birdsall

行政总裁兼董事

T: +1 (613) 967-9655

电子邮件:info@avignonbrands.com

投资者查询:

泰勒·特鲁普

昼夜群

电子邮件:sHRM@avignonbrands.com

对于香菇品牌,法国询价:

雷米·斯卡拉布里尼

Maricom公司

电子邮件:RS@maricom.ca

T:(888)585-马里

CSE和信息服务提供商尚未对此发布的准确性或适当性进行审查,也不承担责任。

前瞻性信息护理声明

除历史事实声明外,本新闻稿还包含适用证券法意义上的某些前瞻性信息。前瞻性信息的特点常常是“计划”、“期望”、“项目”、“意图”、“相信”、“预期”、“估计”和其他类似的词语,或某些事件或条件“可能”或“将”发生的陈述。前瞻性陈述是基于在作出陈述之日的意见和估计,并受到各种风险和不确定因素及其他因素的影响,这些因素可能导致实际事件或结果与前瞻性陈述中的预期大不相同,包括但不限于监管批准的延误或不确定因素,包括CSE的批准。在前瞻性信息中存在着内在的不确定性,包括公司无法控制的因素.我们不能保证本新闻稿中描述的香菇品牌的业务计划将在本新闻稿所描述的条款或时间框架内生效。除法律规定外,如果情况或管理层的估计或意见发生变化,本公司不承担更新前瞻性信息的义务。读者被告诫不要过分依赖前瞻性的陈述.识别可能影响财务结果的风险和不确定性的其他信息载于该公司向加拿大证券监管机构提交的文件,该文件可在www.sedar.com上查阅。

免责声明:中文翻译由腾讯翻译君提供支持,富途对翻译信息的准确性或可靠性所造成的任何损失不承担任何责任。

Copyright©2019 FUTU. All rights reserved. FUTU does not provide any investment advice.